Ibandronate Sodium Tablets

Ibandronate Sodium 150 mg tablets (3‑count blister packs) for the DLA/VA Pharmaceutical Prime Vendor program. Offerors must submit a complete electronic offer via DIBBS that includes Volume 1 (non‑price proposal with technical data, certifications, subcontracting plan, letters of commitment/certification, FDA compliance disclosures, etc.) and Volume 2 (price proposal with unit price per pack for the base year and up to four option years). The solicitation does not require selection among multiple topics or lots. Performance is in the United States with a one‑year base period and four one‑year options (maximum five‑year term); the contract is not set‑aside and includes extensive compliance clauses (e.g., Buy‑American/Trade‑Agreements, child‑labor, FDA cGMP, cost‑recovery fee reporting).

Notice ID

02f72a8db67d448095925ba10a0a7256

Solicitation Number

SPE2D2-25-R-0019

NAICS Code

325412

Classification Code

6505